Blog
RSS FeedPosted by Michael Wonder on 25 Apr 2024
Velsipity receives Health Canada approval for adults with moderately to severely active ulcerative colitis
24 April 2024 - Velsipity is a once daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P ...
Posted by Michael Wonder on 24 Apr 2024
Health Canada authorizes Tecentriq SC (atezolizumab solution for subcutaneous injection), the first cancer immunotherapy subcutaneous injection, for multiple cancer types
23 April 2024 - Roche Canada will be working closely with the pan-Canadian Pharmaceutical Alliance, as well as federal, provincial, ...
Posted by Michael Wonder on 23 Apr 2024
Acadia Pharmaceuticals announces trofinetide new drug submission for treatment of Rett syndrome has been accepted for filing and priority review by Health Canada
22 April 2024 - Acadia Pharmaceuticals today announced that Health Canada has accepted its new drug submission for trofinetide for the ...
Posted by Michael Wonder on 23 Apr 2024
Health Canada approves new indication for Merck’s Prevymis (letermovir) for prevention of cytomegalovirus disease in high risk adult kidney transplant recipients
19 April 2024 - Merck announced that Health Canada has approved a new indication for Prevymis (letermovir) for the prophylaxis ...
Posted by Michael Wonder on 20 Apr 2024
Nora Pharma receives Health Canada approval for Niopeg, a biosimilar of Neulasta
19 April 2024 - Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the ...
Posted by Michael Wonder on 20 Apr 2024
Health Canada approves Keytruda as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2 negative gastric or gastro-oesophageal junction adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy
19 April 2024 - Approval is based on the Phase 3 KEYNOTE-859 trial. ...
Posted by Michael Wonder on 19 Apr 2024
National pharmacare will reduce access to new medicines for 27 million privately insured Canadians
18 April 2024 - The federal Liberal-NDP coalition government recently announced it would work with the provinces to fund universal prescription ...
Posted by Michael Wonder on 12 Apr 2024
Formycon announces commercial launch of FYB201 (ranibizumab) in Canada (Ranopto) and Switzerland (Ranivisio)
11 April 2024 - Commercialization partner Teva markets FYB201 in Canada under the trademark Ranopto and in Switzerland under the trademark ...
Posted by Michael Wonder on 12 Apr 2024
Waiting for new medicines in Canada, Europe, and the United States: study finds Americans get better and faster access to innovative drugs
11 April 2024 - A recent study published by the Canadian Health Policy Institute examined the availability and wait times ...
Posted by Michael Wonder on 10 Apr 2024
New target zero initiative aims to help improve access to new drugs
9 April 2024 - Target Zero is a new initiative that aims to improve the time to access for patients ...
Posted by Michael Wonder on 10 Apr 2024
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
3 April 2024 - AB Science today announced that Health Canada has granted eligibility for reconsideration request for masitinib in ...
Posted by Michael Wonder on 06 Apr 2024
Nurtec ODT is now available in Canada for the treatment of acute migraine
4 April 2024 - More than one billion people worldwide live with migraine, and the World Health Organization classifies migraine ...
Posted by Michael Wonder on 05 Apr 2024
Bausch Health Canada announces first public drug plan listings for Uceris (budesonide) aerosol foam to help address the unmet need for the treatment of mild to moderate distal ulcerative colitis in adults
3 April 2024 - Bausch Health Canada today announced the first public drug plan listings for Uceris (budesonide) aerosol foam ...
Posted by Michael Wonder on 04 Apr 2024
New model validation tool to support economic evaluations of health technologies
1 April 2024 - CADTH has developed a comprehensive and accessible tool to support the validation of economic models used in ...
Posted by Michael Wonder on 03 Apr 2024
Vertex announces new drug submission for exagamglogene autotemcel (exa-cel) has been accepted for priority review by Health Canada for the treatment of sickle cell disease and transfusion-dependent beta thalassaemia
1 April 2024 - Exa-cel is the first CRISPR-based gene-edited therapy to be submitted for Health Canada review. ...